Should I Buy PAHC? PAHC 2026 Analysis

Should You Buy Phibro Animal Health Corp (PAHC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

53.070

1 Day change

6.14%

52 Week Range

56.300

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BUY now (pre-market $40.48). PAHC is a good buy at current levels because fundamentals are accelerating (2026/Q1 showed strong YoY revenue/EPS expansion), Wall Street price targets were recently raised, and options positioning is notably call-leaning. Technicals are neutral/consolidating rather than overbought, and price is sitting right on the pivot (40.45), giving a reasonable entry for an impatient buyer. Main drawback is heavy recent insider selling, which keeps this from being a “high-conviction breakout buy,” but the balance of data still favors buying over waiting.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Setup: Sideways-to-slightly bearish short-term, but stabilizing.

MACD histogram -0.0429 (below zero) but negatively contracting → downside momentum is fading.
RSI(6) 50.7 → neutral; no overbought condition.
Moving averages converging → consolidation range rather than a strong trend.
Key levels: Pivot 40.452 (price ~40.48 sitting on pivot). Resistance R1 42.183 then R2 43.252. Support S1 38.722 then S2 37.653. Practical read: Buying near the pivot with upside to 42–43 is reasonable if the stock can hold above ~38.7 support; otherwise the chart remains range-bound.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Bullish skew.

Open interest put/call ratio 0.36 → substantially more calls than puts outstanding (bullish positioning).
Volume put/call ratio 0.0 → today’s traded flow is effectively calls only (though total volume is small at 12).
IV (30d) ~52.44 vs historical vol ~37.19 → options imply elevated movement expectations, but IV rank ~12.99 / IV percentile ~39.2 suggests IV isn’t extreme versus its own history. Net: Options market leans bullish, with limited evidence of heavy downside hedging.

Technical Summary

Sell

Buy

Positive Catalysts

Earnings catalyst ahead: QDEC 2025 earnings scheduled 2026-02-05 after hours with a conference call 2026-02-05 9:00am ET.
Analyst sentiment improving: both JPMorgan and Morgan Stanley raised price targets recently.
Fundamental momentum: 2026/Q1 delivered strong YoY growth in revenue, net income, and EPS, plus better gross margin.
Options positioning: call-heavy open interest and call-only volume today indicates optimistic sentiment.

Neutral/Negative Catalysts

Insider activity: insiders are selling, with selling amount up 275.18% over the last month (not a supportive signal).
Technicals not in a clear uptrend: MACD still below zero and moving averages converging imply consolidation, not a confirmed breakout.
Broader tape: pre-market S&P 500 is down (-0.38%), which can cap near-term upside.

Financial Performance

Latest reported quarter: 2026/Q1.

Revenue: $363.893M, +39.73% YoY (strong top-line acceleration).
Net income: $26.527M, +280.32% YoY (large profitability improvement).
EPS: $0.65, +282.35% YoY (earnings power expanding rapidly).
Gross margin: 33.22%, +3.62% YoY (improving unit economics). Overall: Clear growth-and-margin expansion profile into the next earnings date.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Price targets moving up; ratings remain constructive.

2025-11-07 JPMorgan: raised PT to $50 from $45; Overweight.
2025-11-07 Morgan Stanley: raised PT to $45 from $34; Equal Weight. Wall Street pros: accelerating fundamentals, raised targets, potential upside versus current ~$40. Wall Street cons: not universally a “buy” (one Equal Weight), and insider selling can temper conviction. Politicians/influential buying/selling: No recent congress trading data available in the last 90 days.

2 Analyst Rating

Wall Street analysts forecast PAHC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAHC is 47.5 USD with a low forecast of 45 USD and a high forecast of 50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 50.000

Low

Averages

47.5

High

Current: 50.000

Low

Averages

47.5

High

Morgan Stanley

Equal Weight

maintain

$45 -> $49

AI Analysis

2026-02-06

New

Reason

Morgan Stanley

Price Target

$45 -> $49

AI Analysis

2026-02-06

New

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Phibro Animal Health to $49 from $45 and keeps an Equal Weight rating on the shares. Phibro's latest print reflects solid execution, particularly around its Zoetis MFA transaction/Animal Health segment/cost management, with a Q2 beat, raised FY26 guidance, and notable margin expansion, the analyst tells investors in a research note.

JPMorgan

NULL -> Overweight

upgrade

$45 -> $50

2025-11-07

Reason

JPMorgan

Price Target

$45 -> $50

2025-11-07

upgrade

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Phibro Animal Health to $50 from $45 and keeps an Overweight rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PAHC

Unlock Now

PAHC Should I Buy

PAHC Should I Buy

Should You Buy Phibro Animal Health Corp (PAHC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch